1. Home
  2. Vol 53, No 3 (2021)
  3. Saifuddin

COVID Arm After Moderna Booster in Healthcare Worker: A Case Report

Anshari Saifuddin, Sukamto Koesnoe, Nia Kurniati, Sondang Sirait, Riesye Arisanty, Evy Yunihastuti

Abstract


SARS CoV-2 virus has infected more than 200 million people worldwide and more than 4.4 million in Indonesia. The vaccination program has become one of the solutions launched by many countries globally, including Indonesia, to reduce the transmission rate of COVID-19. Various vaccination platforms are produced, such as inactivated, viral vector, mRNA, and protein subunit. The vaccination booster program with mRNA platform (Moderna) was launched by the Indonesian government to give better protection for health care workers, particularly from delta variant. In this case report, we discuss one of the typical side effects of Moderna vaccine, which is referred to as the COVID arm.


Keywords


COVID arm; COVID-19; booster; Moderna; vaccination; healthcare worker

References


Worldometers. Coronavirus cases in world. [cited 2021 August 26]. Available from https://www.worldometers.info/coronavirus/

Kementerian Komunikasi dan Informatika. Sebaran kasus COVID-19 di Indonesia. [cited 2021 August 26]. Available from https://covid19.go.id/

Kementerian Kesehatan RI. Materi Penanganan COVID-19. Kemenkes. Desember 2020.

Tim mitigasi Ikatan Dokter Indonesia. Data kematian dokter di Indonesia akibat COVID-19. IDI. 2021

Lingren AL, Austin AH, Welsh K. COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis. J Primary Care Comm Health. 2021;12:1-5

Allergic Reactions. Centers for Disease Control and Prevention. [cited 2021 August 26]. Available from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html

Baen LR, Sahly E, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-16.

Blumenthal KG, Freeman EF, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2.N Engl J Med. 2021;384:1273-7.

Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130:25-43.

McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141:463-72.

U.S. Food and Drug Administration. Fact Sheet for Recipients and Caregivers. Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 16 Years of Age and Older [fact sheet]. [cited 2021 August 26]. Available from https://www.fda.gov/ media/144414/download#page=2

U.S. Food and Drug Administration. Fact Sheet for Recipients and Caregivers. Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) in Individuals 18 Years of Age and Older [fact sheet].[cited 2021 August 26]. Available from https://www.fda.gov/ media/144638/download#page=2

Allergic Reactions. Centers for Disease Control and Prevention. [cited 2021 August 26]. Available from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic- reaction.html

Fisher AA. Immediate and delayed allergic contact reactions to polyethylene glycol. Contact Dermatitis. 1978;4:135-8.

Halperin S, Kohl KS, Gidudu J, et al. Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5803-20.

Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med. 1996;335(8):547-54.

Weng QY, Raff AB, Cohen JM, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153(2):141-6.


Full Text: PDF

Refbacks

  • There are currently no refbacks.